Want to see ONC full AI Analyst Report?
ONC Stock Chart & Stats
$323.87
--
Market closed
$323.87
--
Day’s Range― - ―
52-Week Range$253.95 - $385.22
Previous CloseN/A
VolumeN/A
Average Volume (3M)338.29K
Market Cap
$37.02B
Enterprise Value$31.60K
Total Cash (Recent Filing)$4.79B
Total Debt (Recent Filing)$1.15B
Price to Earnings (P/E)5.1
Beta0.73
Next Earnings
Aug 05, 2026EPS Estimate
1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)49.88
Shares Outstanding109,720,300
10 Day Avg. Volume391,980
30 Day Avg. Volume338,290
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)7.60
Price to Sales (P/S)6.20
P/FCF Ratio35.18
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$403.45Price Target Upside24.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)6.84
Revenue Forecast (FY)$6.51B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow TurnaroundSustained positive operating and free cash flow in 2025 and TTM indicates the company has moved from financing-dependent operations toward internal funding of growth. This strengthens long-term solvency, supports reinvestment in R&D/commercialization, and reduces reliance on external capital if maintained.
High Gross ProfitabilityExceptionally strong gross margins (~high-80% range) combined with rapid revenue scaling imply durable product economics and pricing power typical of successful oncology drugs. High gross profitability provides structural capacity to absorb R&D and commercial expenses while preserving long-term operating leverage as sales scale.
Regulatory Approval Expands FootprintAccelerated FDA approval for BEQALZI is a structural commercial inflection: it establishes U.S. market access, broadens global footprint, and validates the BCL2 franchise. This durable regulatory milestone supports recurring revenue potential and strengthens competitive position in a difficult post-BTK treatment setting.
Bears Say
Legacy Cash Burn And Rising DebtA history of substantial losses and increased total debt leaves the balance sheet still normalizing. Elevated leverage after multi-year burn reduces financial flexibility and increases refinancing and interest-rate sensitivity, constraining strategic optionality if commercial performance weakens.
Modest Net MarginDespite high gross margins, TTM net margin near 9% is modest relative to growth and leaves limited cushion for setbacks. Sustained investment needs for confirmatory trials and commercialization could compress net margins unless revenue growth continues to outpace operating cost expansion.
Cash Conversion WeaknessOperating cash flow materially below EBITDA and recent negative cash flow indicate weaker cash conversion. This structural volatility makes earnings less reliable as a liquidity source, raising the risk that the company may need external financing during adverse periods or to fund confirmatory studies.
BeOne Medicines News
ONC FAQ
What was BeOne Medicines’s price range in the past 12 months?
BeOne Medicines lowest stock price was $253.95 and its highest was $385.22 in the past 12 months.
What is BeOne Medicines’s market cap?
BeOne Medicines’s market cap is $37.02B.
When is BeOne Medicines’s upcoming earnings report date?
BeOne Medicines’s upcoming earnings report date is Aug 05, 2026 which is in 13 days.
How were BeOne Medicines’s earnings last quarter?
BeOne Medicines released its earnings results on May 06, 2026. The company reported $1.96 earnings per share for the quarter, beating the consensus estimate of $1.076 by $0.884.
Is BeOne Medicines overvalued?
According to Wall Street analysts BeOne Medicines’s price is currently Undervalued.
Does BeOne Medicines pay dividends?
BeOne Medicines does not currently pay dividends.
What is BeOne Medicines’s EPS estimate?
BeOne Medicines’s EPS estimate is 1.62.
How many shares outstanding does BeOne Medicines have?
BeOne Medicines has 109,720,300 shares outstanding.
What happened to BeOne Medicines’s price movement after its last earnings report?
BeOne Medicines reported an EPS of $1.96 in its last earnings report, beating expectations of $1.076. Following the earnings report the stock price went up 5.321%.
Which hedge fund is a major shareholder of BeOne Medicines?
Currently, no hedge funds are holding shares in ONC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$403.45 (24.57% Upside)
$403.45 (24.57% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 54.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.16%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
46.43%
Trailing 12-Months
Company Description
BeOne Medicines
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.
ONC Stock 12 Month Forecast
Average Price Target
$403.45
▲(24.57% Upside)
Technical Analysis
Ownership Overview
67.87% Insiders
12.24% Mutual Funds
0.04% Other Institutional Investors
18.75% Public Companies and
Individual Investors